Biochem/physiol Actions

3,6-DMAD is an acridine derivative that selectively suppresses ER stress- (300 nM Thapsigargin) induced HT1080 cellular XBP1 mRNA splicing (Eff. conc. 500 nM), but not eIF2a phosphorylation, by directly inhibiting IRE1? RNase (endoribonuclease) activity and disrupting IRE1A oligomerization. 3,6-DMAD is shown to exhibit anti-multiple myeloma efficacy in cultures in vitro (%survival/[3,6-DMAD]/cell line/24 h = 13%/4 M/RPMI 8226 and 8%/1 μM/MM1.R) and completely suppress the expansion of established RPMI 8226 tumor in mice in vivo when administered via intraperitoneal injection (10 mg/kg q.o.d.).

3,6-DMAD is also called as N⁹-(3-(dimethylamino)propyl)-N³,N³,N⁶,N6-tetramethylacridine-3,6,9-triamine. It prevents the development of multiple myeloma (MM) tumor xenografts.

Packaging

5, 25 mg in glass bottle